Evidence map›Paper›PMID 35414031›Full record

ArticleOrphanet journal of rare diseases2022

Increased COVID-19 mortality rate in rare disease patients: a retrospective cohort study in participants of the Genomics England 100,000 Genomes project.

Huayu Zhang, Johan H Thygesen, Ting Shi, Georgios V Gkoutos, Harry Hemingway, Bruce Guthrie, Honghan Wu, Genomics England Research Consortium

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Huayu ZhangAdvanced Care Research Centre, Usher Institute, University of Edinburgh, Edinburgh, UK.
Johan H ThygesenInstitute of Health Informatics, University College London, London, UK.
Ting ShiCentre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
Georgios V GkoutosInstitute of Cancer and Genomics, University of Birmingham, Birmingham, UK.
Harry HemingwayInstitute of Health Informatics, University College London, London, UK.
Bruce GuthrieAdvanced Care Research Centre, Usher Institute, University of Edinburgh, Edinburgh, UK.
Honghan WuInstitute of Health Informatics, University College London, London, UK. honghan.wu@ucl.ac.uk.ORCID 0000-0002-0213-5668
Genomics England Research Consortium
University of Edinburgh · GBUniversity College London · GBGenomics (United Kingdom) · GBHealth Data Research UK · GB

Funding

Cancer Research UKDepartment of Health NIHR202639Medical Research Council MC_PC_18029Medical Research Council MR/S004149/1Medical Research Council MR/S004149/2Wellcome TrustWellcome Trust PIII0054/005Wellcome Trust PIII026/013
6 · The paper itself

Abstract

backgroundSeveral common conditions have been widely recognised as risk factors for COVID-19 related death, but risks borne by people with rare diseases are largely unknown. Therefore, we aim to estimate the difference of risk for people with rare diseases comparing to the unaffected.

methodTo estimate the correlation between rare diseases and COVID-19 related death, we performed a retrospective cohort study in Genomics England 100k Genomes participants, who tested positive for Sars-Cov-2 during the first wave (16-03-2020 until 31-July-2020) of COVID-19 pandemic in the UK (n = 283). COVID-19 related mortality rates were calculated in two groups: rare disease patients (n = 158) and unaffected relatives (n = 125). Fisher's exact test and logistic regression was used for univariable and multivariable analysis, respectively.

resultsPeople with rare diseases had increased risk of COVID19-related deaths compared to the unaffected relatives (OR [95% CI] = 3.47 [1.21- 12.2]). Although, the effect was insignificant after adjusting for age and number of comorbidities (OR [95% CI] = 1.94 [0.65-5.80]). Neurology and neurodevelopmental diseases was significantly associated with COVID19-related death in both univariable (OR [95% CI] = 4.07 [1.61-10.38]) and multivariable analysis (OR [95% CI] = 4.22 [1.60-11.08]).

conclusionsOur results showed that rare disease patients, especially ones affected by neurology and neurodevelopmental disorders, in the Genomics England cohort had increased risk of COVID-19 related death during the first wave of the pandemic in UK. The high risk is likely associated with rare diseases themselves, while we cannot rule out possible mediators due to the small sample size. We would like to raise the awareness that rare disease patients may face increased risk for COVID-19 related death. Proper considerations for rare disease patients should be taken when relevant policies (e.g., returning to workplace) are made.

Indexed as

COVID-19Cohort StudiesEnglandGenomicsHumansPandemicsRare DiseasesRetrospective StudiesSARS-CoV-2COVID-19 mortalityRare diseases

Identifiers

PMID35414031
PMCPMC9003178
OpenAlexW4223429546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.